Liver transplantation for cholangiocarcinoma: Current status and new insights.

World J Hepatol

Gonzalo Sapisochín, Elena Fernández de Sevilla, Juan Echeverri, Ramón Charco, Department of HBP Surgery and Transplantation, Hospital Universitario Vall d'Hebron, Universidad Autónoma de Barcelona, 08037 Barcelona, Spain.

Published: October 2015

Cholangiocarcinoma is a malignant tumor of the biliary system that can be classified into intrahepatic (iCCA), perihiliar (phCCA) and distal. Initial experiences with orthotopic liver transplantation (OLT) for patients with iCCA and phCCA had very poor results and this treatment strategy was abandoned. In the last decade, thanks to a strict selection process and a neoadjuvant chemoradiation protocol, the results of OLT for patients with non-resectable phCCA have been shown to be excellent and this strategy has been extended worldwide in selected transplant centers. Intrahepatic cholangiocarcinoma is a growing disease in most countries and can be diagnosed both in cirrhotic and in non-cirrhotic livers. Even though OLT is contraindicated in most centers, recent investigations analyzing patients that were transplanted with a misdiagnosis of HCC and were found to have an iCCA have shown encouraging results. There is some information suggesting that patients with early stages of the disease could benefit from OLT. In this review we analyze the current state-of-the-art of OLT for cholangiocarcinoma as well as the new insights and future perspectives.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598610PMC
http://dx.doi.org/10.4254/wjh.v7.i22.2396DOI Listing

Publication Analysis

Top Keywords

liver transplantation
8
olt patients
8
olt
5
cholangiocarcinoma
4
transplantation cholangiocarcinoma
4
cholangiocarcinoma current
4
current status
4
status insights
4
insights cholangiocarcinoma
4
cholangiocarcinoma malignant
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!